[68Ga]Ga-PSMA-11 PET/CT、[68Ga]Ga-NODAGAZOL PET/CT与[99mTc]Tc-MDP骨显像用于前列腺癌骨转移核素显像的前瞻性个体内比较
前瞻性纳入18例晚期前列腺癌患者(初诊分期组10例、再分期组8例),个体内比较[68Ga]Ga-PSMA-11 PET/CT、[68Ga]Ga-NODAGAZOL PET/CT与[99mTc]Tc-MDP骨显像对骨转移灶的检出。初诊分期组三种方法检出灶数分别为322、288、261(p=0.578);再分期组PSMA-11与NODAGAZOL分别检出152与191个灶(p=0.529)。作者认为初诊分期时PSMA-11 PET/CT可能检出更多病灶,再分期时NODAGAZOL PET/CT可能检出更多不表达PSMA的骨病灶。
要点
- 初诊分期组PSMA-11、NODAGAZOL与骨显像检出骨转移灶分别为322、288、261个,p=0.578。
- 再分期组PSMA-11与NODAGAZOL分别检出152与191个骨转移灶,p=0.529。
- 2例PSMA-11阴性患者中NODAGAZOL分别检出1个与12个骨转移灶。
核心结论
- 在晚期前列腺癌患者中,[68Ga]Ga-PSMA-11 PET/CT在骨转移初诊分期时可能较[68Ga]Ga-NODAGAZOL PET/CT和[99mTc]Tc-MDP骨显像检出更多病灶。
- 在接受PSMA放射性配体治疗并出现PSA进展的患者中,[68Ga]Ga-NODAGA PET/CT是检出不表达PSMA的骨病灶更合适的显像方法。
- 在再分期情形下,[68Ga]Ga-NODAGAZOL PET/CT可能较[68Ga]Ga-PSMA-11 PET/CT检出更多病灶。
研究设计与样本
- 前瞻性招募两个队列(初诊分期队列与再分期队列)的晚期前列腺癌患者,共纳入18例,中位年龄68岁(范围48-80),中位Gleason评分8。
- 初诊分期队列为骨显像显示骨转移且未接受治疗的10例患者,中位PSA 119.26 ng/mL(范围4.63-18,948.00),随后行[68Ga]Ga-PSMA-11 PET/CT与[68Ga]Ga-NODAGAZOL PET/CT。
- 再分期队列为既往接受过PSMA放射性配体治疗且出现PSA进展的8例患者,中位PSA 48.56 ng/mL(范围6.51-3175.00),行[68Ga]Ga-PSMA-11 PET/CT与[68Ga]Ga-NODAGAZOL PET/CT。
- 对两队列骨转移灶进行按患者与按病灶分析,并比较各扫描所见。
主要发现
- 初诊分期队列中,[68Ga]Ga-PSMA-11 PET/CT、[68Ga]Ga-NODAGAZOL PET/CT与骨显像检出的骨转移灶分别为322、288与261个,p=0.578。
- 再分期队列中,[68Ga]Ga-PSMA-11 PET/CT与[68Ga]Ga-NODAGAZOL PET/CT分别检出152与191个骨转移灶,p=0.529。
- 2例[68Ga]Ga-PSMA-11 PET/CT阴性的患者中,[68Ga]Ga-NODAGAZOL在一例检出1个骨转移灶、在另一例检出12个骨转移灶。
关键数值与推荐
- 初诊分期队列中位PSA为119.26 ng/mL(范围4.63-18,948.00),再分期队列中位PSA为48.56 ng/mL(范围6.51-3175.00)。
- 初诊分期队列三种显像检出骨转移灶数比较p=0.578,再分期队列两种PET/CT检出骨转移灶数比较p=0.529。
临床怎么用
- 作者认为,晚期前列腺癌骨转移初诊分期时[68Ga]Ga-PSMA-11 PET/CT可能检出更多病灶。
- 作者认为,PSMA放射性配体治疗后PSA进展的患者中[68Ga]Ga-NODAGA PET/CT更适于检出不表达PSMA的骨病灶。
- 作者认为,再分期情形下[68Ga]Ga-NODAGAZOL PET/CT可能较[68Ga]Ga-PSMA-11 PET/CT检出更多病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate cancer (PCa) commonly metastasizes to the bones. There are several radionuclide techniques for imaging PCa skeletal metastases. We aimed to compare the lesion detection rate of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGA-zoledronate ([68Ga]Ga-NODAGAZOL) PET/CT, and [99mTc]Tc-MDP bone scan in the assessment of bone metastases in patients with advanced PCa. METHODS: We prospectively recruited two cohorts of patients (staging and re-staging cohorts) with advanced prostate cancer. The staging cohort was treatment-naïve PCa patients who showed skeletal metastases on bone scan. These patients were subsequently imaged with [68Ga]Ga-PSMA-11 PET/CT and [68Ga]Ga-NODAGAZOL PET/CT. Re-staging cohort was patients who were previously treated with PSMA-based radioligand therapy and were experiencing PSA progression. The re-staging cohort was imaged with [68Ga]Ga-PSMA-11 PET/CT and [68Ga]Ga-NODAGAZOL PET/CT. We performed a per-patient and per-lesion analysis of skeletal metastases in both cohorts and made a comparison between scan findings. RESULTS: Eighteen patients were included with a median age of 68 years (range = 48-80) and a median Gleason score of 8. There were ten patients in the staging cohort with a median PSA of 119.26 ng/mL (range = 4.63-18,948.00) and eight patients in the re-staging cohort with a median PSA of 48.56 ng/mL (range = 6.51-3175.00). In the staging cohort, skeletal metastases detected by [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and bone scan were 322, 288, and 261, respectively, p = 0.578. In the re-staging cohort, [68Ga]Ga-PSMA-11 PET/CT and [68Ga]Ga-NODAGAZOL PET/CT detected 152 and 191 skeletal metastases, respectively, p = 0.529. In two patients with negative [68Ga]Ga-PSMA-11 PET/CT findings, [68Ga]Ga-NODAGAZOL detected one skeletal metastasis in one patient and 12 skeletal metastases in the other. CONCLUSION: In patients with advanced prostate cancer, [68Ga]Ga-PSMA-11 PET/CT may detect more lesions than [68Ga]Ga-NODAGAZOL PET/CT and [99mTc]Tc-MDP bone scan for the staging of skeletal metastases. In patients who experience PSA progression on PSMA-based radioligand therapy, [68Ga]Ga-NODAGA PET/CT is a more suitable imaging modality for the detection of skeletal lesions not expressing PSMA. In the setting of re-staging, [68Ga]Ga-NODAGAZOL PET/CT may detect more lesions than [68Ga]Ga-PSMA-11 PET/CT.
引用
- Lawal IO, Mokoala KMG, Mahapane J, et al. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. Eur J Nucl Med Mol Imaging. 2020. PMID: 32424485. doi:10.1007/s00259-020-04867-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。